DNX-2401 (Formerly Known as Delta-24-RGD-4C) for Recurrent Malignant Gliomas

Summary

The goal of this clinical research study is to find the highest tolerable dose of DNX-2401 that can be injected directly into brain tumors and into the surrounding brain tissue where tumor cells can multiply. A second goal is to study how the new drug DNX-2401 affects brain tumor cells and the body in general.

Timeline

Start

2009-02

Primary completion

2015-02

Completion

2015-02

Publications

• Shin DH, Jiang H, Gillard AG, Kim D, Fan X, Singh SK, Nguyen TT, Sohoni SS, Lopez-Rivas AR, Parthasarathy A, Ene CI, Gumin J, Lang FF, Alonso MM, Gomez-Manzano C, Fueyo J. Chimeric oncolytic adenovirus evades neutralizing antibodies from human patients and exhibits enhanced anti-glioma efficacy in immunized mice. Mol Ther. 2024 Mar 6;32(3):722-733. doi: 10.1016/j.ymthe.2024.01.035. Epub 2024 Feb 3.
• Lang FF, Conrad C, Gomez-Manzano C, Yung WKA, Sawaya R, Weinberg JS, Prabhu SS, Rao G, Fuller GN, Aldape KD, Gumin J, Vence LM, Wistuba I, Rodriguez-Canales J, Villalobos PA, Dirven CMF, Tejada S, Valle RD, Alonso MM, Ewald B, Peterkin JJ, Tufaro F, Fueyo J. Phase I Study of DNX-2401 (Delta-24-RGD) Oncolytic Adenovirus: Replication and Immunotherapeutic Effects in Recurrent Malignant Glioma. J Clin Oncol. 2018 May 10;36(14):1419-1427. doi: 10.1200/JCO.2017.75.8219. Epub 2018 Feb 12.

Drugs

Indications